Tags

Type your tag names separated by a space and hit enter

Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT.
Ann Rheum Dis 2010; 69(8):1459-64AR

Abstract

BACKGROUND

Knee osteoarthritis (OA) is a major cause of pain and functional limitation in older adults, yet longer-term studies of medical treatment of OA are limited.

OBJECTIVE

To evaluate the efficacy and safety of glucosamine and chondroitin sulphate (CS), alone or in combination, as well as celecoxib and placebo on painful knee OA over 2 years.

METHODS

A 24-month, double-blind, placebo-controlled study, conducted at nine sites in the US ancillary to the Glucosamine/chondroitin Arthritis Intervention Trial, enrolled 662 patients with knee OA who satisfied radiographic criteria (Kellgren/Lawrence grade 2 or 3 changes and baseline joint space width of at least 2 mm). This subset continued to receive their randomised treatment: glucosamine 500 mg three times daily, CS 400 mg three times daily, the combination of glucosamine and CS, celecoxib 200 mg daily, or placebo over 24 months. The primary outcome was a 20% reduction in Western Ontario and McMaster University Osteoarthritis Index (WOMAC) pain over 24 months. Secondary outcomes included an Outcome Measures in Rheumatology/Osteoarthritis Research Society International response and change from baseline in WOMAC pain and function.

RESULTS

Compared with placebo, the odds of achieving a 20% reduction in WOMAC pain were celecoxib: 1.21, glucosamine: 1.16, combination glucosamine/CS: 0.83 and CS alone: 0.69, and were not statistically significant.

CONCLUSIONS

Over 2 years, no treatment achieved a clinically important difference in WOMAC pain or function as compared with placebo. However, glucosamine and celecoxib showed beneficial but not significant trends. Adverse reactions were similar among treatment groups and serious adverse events were rare for all treatments.

Authors+Show Affiliations

University of Utah School of Medicine, 30E 1900 S SOM 4B200, Salt Lake City UT 84132, USA. allen.sawitzke@hsc.utah.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

20525840

Citation

Sawitzke, Allen D., et al. "Clinical Efficacy and Safety of Glucosamine, Chondroitin Sulphate, Their Combination, Celecoxib or Placebo Taken to Treat Osteoarthritis of the Knee: 2-year Results From GAIT." Annals of the Rheumatic Diseases, vol. 69, no. 8, 2010, pp. 1459-64.
Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis. 2010;69(8):1459-64.
Sawitzke, A. D., Shi, H., Finco, M. F., Dunlop, D. D., Harris, C. L., Singer, N. G., ... Clegg, D. O. (2010). Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Annals of the Rheumatic Diseases, 69(8), pp. 1459-64. doi:10.1136/ard.2009.120469.
Sawitzke AD, et al. Clinical Efficacy and Safety of Glucosamine, Chondroitin Sulphate, Their Combination, Celecoxib or Placebo Taken to Treat Osteoarthritis of the Knee: 2-year Results From GAIT. Ann Rheum Dis. 2010;69(8):1459-64. PubMed PMID: 20525840.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. AU - Sawitzke,Allen D, AU - Shi,Helen, AU - Finco,Martha F, AU - Dunlop,Dorothy D, AU - Harris,Crystal L, AU - Singer,Nora G, AU - Bradley,John D, AU - Silver,David, AU - Jackson,Christopher G, AU - Lane,Nancy E, AU - Oddis,Chester V, AU - Wolfe,Fred, AU - Lisse,Jeffrey, AU - Furst,Daniel E, AU - Bingham,Clifton O, AU - Reda,Domenic J, AU - Moskowitz,Roland W, AU - Williams,H James, AU - Clegg,Daniel O, Y1 - 2010/06/04/ PY - 2010/6/8/entrez PY - 2010/6/8/pubmed PY - 2010/8/14/medline SP - 1459 EP - 64 JF - Annals of the rheumatic diseases JO - Ann. Rheum. Dis. VL - 69 IS - 8 N2 - BACKGROUND: Knee osteoarthritis (OA) is a major cause of pain and functional limitation in older adults, yet longer-term studies of medical treatment of OA are limited. OBJECTIVE: To evaluate the efficacy and safety of glucosamine and chondroitin sulphate (CS), alone or in combination, as well as celecoxib and placebo on painful knee OA over 2 years. METHODS: A 24-month, double-blind, placebo-controlled study, conducted at nine sites in the US ancillary to the Glucosamine/chondroitin Arthritis Intervention Trial, enrolled 662 patients with knee OA who satisfied radiographic criteria (Kellgren/Lawrence grade 2 or 3 changes and baseline joint space width of at least 2 mm). This subset continued to receive their randomised treatment: glucosamine 500 mg three times daily, CS 400 mg three times daily, the combination of glucosamine and CS, celecoxib 200 mg daily, or placebo over 24 months. The primary outcome was a 20% reduction in Western Ontario and McMaster University Osteoarthritis Index (WOMAC) pain over 24 months. Secondary outcomes included an Outcome Measures in Rheumatology/Osteoarthritis Research Society International response and change from baseline in WOMAC pain and function. RESULTS: Compared with placebo, the odds of achieving a 20% reduction in WOMAC pain were celecoxib: 1.21, glucosamine: 1.16, combination glucosamine/CS: 0.83 and CS alone: 0.69, and were not statistically significant. CONCLUSIONS: Over 2 years, no treatment achieved a clinically important difference in WOMAC pain or function as compared with placebo. However, glucosamine and celecoxib showed beneficial but not significant trends. Adverse reactions were similar among treatment groups and serious adverse events were rare for all treatments. SN - 1468-2060 UR - https://www.unboundmedicine.com/medline/citation/20525840/Clinical_efficacy_and_safety_of_glucosamine_chondroitin_sulphate_their_combination_celecoxib_or_placebo_taken_to_treat_osteoarthritis_of_the_knee:_2_year_results_from_GAIT_ L2 - http://ard.bmj.com/cgi/pmidlookup?view=long&pmid=20525840 DB - PRIME DP - Unbound Medicine ER -